2011 Fiscal Year Final Research Report
Analysis of aberrantly activated receptor tyrosine kinase and development of molecular targeting therapy in small animals with malignancies.
| Project/Area Number |
21580395
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Clinical veterinary science
|
|---|
| Research Institution | Nippon Veterinary and Life Science University |
|---|
Principal Investigator |
MAKOTO Bonkobara 日本獣医生命科学大学, 獣医学部, 准教授 (50343611)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TOSHIRO Arai 日本獣医生命科学大学, 獣医学部, 教授 (70184257)
ONO Kenichiro 日本獣医生命科学大学, 獣医学部, 客員教授 (50111480)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | c-kit / 猫 / 肥満細胞腫 / チロシンキナーゼ / 分子標的療法 |
|---|
| Research Abstract |
The mutation status of KIT and effects of imatinib on the mutant KIT were investigated in vitro and in clinical cases of cats and dogs with mast cell tumors(MCTs). Mutations in c-kit exon 8 and 9 were identified in tumor cells from cats and dogs with MCTs. These mutations caused constitutive phosphorylation of KIT. Imatinib suppressed the phosphorylation of the mutant KIT. A beneficial response to imatinib was observed in cats and dogs that had a mutation in c-kit exon 8 or 9.MCTs with mutations in c-kit exon 8 and 9 are potentially sensitive to imatinib in dogs and cats.
|
